Genus (GNS) Competitors

GBX 2,312 +26.00 (+1.14%)

As of 03:39 AM Eastern

GNS vs. IGG, DPH, HWDN, CTY, and SMWH

Should you buy Genus stock or one of its competitors? MarketBeat compares Genus with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Genus include IG Group (IGG), Dechra Pharmaceuticals (DPH), Howden Joinery Group (HWDN), City of London (CTY), and WH Smith (SMWH). These companies are all part of the "personal services" industry.

How does Genus compare to IG Group?

IG Group (LON:IGG) and Genus (LON:GNS) are both personal services companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

74.0% of IG Group shares are held by institutional investors. Comparatively, 53.1% of Genus shares are held by institutional investors. 1.2% of IG Group shares are held by insiders. Comparatively, 0.7% of Genus shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

IG Group has a net margin of 35.26% compared to Genus' net margin of 7.07%. IG Group's return on equity of 20.91% beat Genus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IG Group	35.26%	20.91%	10.37%
Genus	7.07%	9.70%	3.31%

IG Group has a beta of 0.487, indicating that its stock price is 51% less volatile than the broader market. Comparatively, Genus has a beta of 0.895, indicating that its stock price is 11% less volatile than the broader market.

IG Group presently has a consensus target price of GBX 1,302, suggesting a potential downside of 14.06%. Genus has a consensus target price of GBX 3,216.67, suggesting a potential upside of 39.13%. Given Genus' higher probable upside, analysts clearly believe Genus is more favorable than IG Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IG Group	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
Genus	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Genus had 5 more articles in the media than IG Group. MarketBeat recorded 6 mentions for Genus and 1 mentions for IG Group. Genus' average media sentiment score of 0.21 beat IG Group's score of 0.00 indicating that Genus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IG Group	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genus	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

IG Group pays an annual dividend of GBX 46.50 per share and has a dividend yield of 3.1%. Genus pays an annual dividend of GBX 32 per share and has a dividend yield of 1.4%. IG Group pays out 44.2% of its earnings in the form of a dividend. Genus pays out 45.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. IG Group is clearly the better dividend stock, given its higher yield and lower payout ratio.

IG Group has higher revenue and earnings than Genus. IG Group is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IG Group	£949.10M	5.28	£533.35M	£105.10	14.41
Genus	£672M	2.28	£7.87M	£71.00	32.56

Summary

IG Group beats Genus on 12 of the 17 factors compared between the two stocks.

How does Genus compare to Dechra Pharmaceuticals?

Genus (LON:GNS) and Dechra Pharmaceuticals (LON:DPH) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

Genus pays an annual dividend of GBX 32 per share and has a dividend yield of 1.4%. Dechra Pharmaceuticals pays an annual dividend of GBX 45 per share. Genus pays out 45.1% of its earnings in the form of a dividend. Dechra Pharmaceuticals pays out -18,000.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

53.1% of Genus shares are held by institutional investors. Comparatively, 105.5% of Dechra Pharmaceuticals shares are held by institutional investors. 0.7% of Genus shares are held by insiders. Comparatively, 9.3% of Dechra Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Genus has higher earnings, but lower revenue than Dechra Pharmaceuticals. Dechra Pharmaceuticals is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genus	£672M	2.28	£7.87M	£71.00	32.56
Dechra Pharmaceuticals	£761.50M	0.00	-£27.90M	-£0.25	N/A

In the previous week, Genus had 6 more articles in the media than Dechra Pharmaceuticals. MarketBeat recorded 6 mentions for Genus and 0 mentions for Dechra Pharmaceuticals. Genus' average media sentiment score of 0.21 beat Dechra Pharmaceuticals' score of 0.00 indicating that Genus is being referred to more favorably in the media.

Company	Overall Sentiment
Genus	Neutral
Dechra Pharmaceuticals	Neutral

Genus has a beta of 0.895, suggesting that its stock price is 11% less volatile than the broader market. Comparatively, Dechra Pharmaceuticals has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market.

Genus currently has a consensus target price of GBX 3,216.67, indicating a potential upside of 39.13%. Given Genus' stronger consensus rating and higher probable upside, equities analysts plainly believe Genus is more favorable than Dechra Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genus	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Dechra Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Genus has a net margin of 7.07% compared to Dechra Pharmaceuticals' net margin of -3.66%. Genus' return on equity of 9.70% beat Dechra Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genus	7.07%	9.70%	3.31%
Dechra Pharmaceuticals	-3.66%	-3.92%	0.75%

Summary

Genus beats Dechra Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

How does Genus compare to Howden Joinery Group?

Genus (LON:GNS) and Howden Joinery Group (LON:HWDN) are both personal services companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

Genus pays an annual dividend of GBX 32 per share and has a dividend yield of 1.4%. Howden Joinery Group pays an annual dividend of GBX 21.30 per share and has a dividend yield of 2.9%. Genus pays out 45.1% of its earnings in the form of a dividend. Howden Joinery Group pays out 43.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Howden Joinery Group is clearly the better dividend stock, given its higher yield and lower payout ratio.

53.1% of Genus shares are held by institutional investors. Comparatively, 67.4% of Howden Joinery Group shares are held by institutional investors. 0.7% of Genus shares are held by company insiders. Comparatively, 0.9% of Howden Joinery Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Howden Joinery Group has higher revenue and earnings than Genus. Howden Joinery Group is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genus	£672M	2.28	£7.87M	£71.00	32.56
Howden Joinery Group	£2.42B	1.64	£253.42M	£49.00	15.02

In the previous week, Genus had 6 more articles in the media than Howden Joinery Group. MarketBeat recorded 6 mentions for Genus and 0 mentions for Howden Joinery Group. Genus' average media sentiment score of 0.21 beat Howden Joinery Group's score of 0.00 indicating that Genus is being referred to more favorably in the media.

Company	Overall Sentiment
Genus	Neutral
Howden Joinery Group	Neutral

Genus has a beta of 0.895, suggesting that its share price is 11% less volatile than the broader market. Comparatively, Howden Joinery Group has a beta of 1.298, suggesting that its share price is 30% more volatile than the broader market.

Howden Joinery Group has a net margin of 11.07% compared to Genus' net margin of 7.07%. Howden Joinery Group's return on equity of 23.58% beat Genus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genus	7.07%	9.70%	3.31%
Howden Joinery Group	11.07%	23.58%	10.70%

Genus currently has a consensus target price of GBX 3,216.67, indicating a potential upside of 39.13%. Howden Joinery Group has a consensus target price of GBX 924, indicating a potential upside of 25.54%. Given Genus' stronger consensus rating and higher possible upside, equities research analysts clearly believe Genus is more favorable than Howden Joinery Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genus	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Howden Joinery Group	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Howden Joinery Group beats Genus on 10 of the 18 factors compared between the two stocks.

How does Genus compare to City of London?

City of London (LON:CTY) and Genus (LON:GNS) are both personal services companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

8.7% of City of London shares are owned by institutional investors. Comparatively, 53.1% of Genus shares are owned by institutional investors. 0.1% of City of London shares are owned by insiders. Comparatively, 0.7% of Genus shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

City of London has a net margin of 97.40% compared to Genus' net margin of 7.07%. City of London's return on equity of 22.92% beat Genus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
City of London	97.40%	22.92%	4.00%
Genus	7.07%	9.70%	3.31%

City of London has a beta of 0.8609003, meaning that its stock price is 14% less volatile than the broader market. Comparatively, Genus has a beta of 0.895, meaning that its stock price is 11% less volatile than the broader market.

City of London pays an annual dividend of GBX 21.45 per share and has a dividend yield of 3.9%. Genus pays an annual dividend of GBX 32 per share and has a dividend yield of 1.4%. City of London pays out 18.8% of its earnings in the form of a dividend. Genus pays out 45.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. City of London is clearly the better dividend stock, given its higher yield and lower payout ratio.

Genus has a consensus price target of GBX 3,216.67, indicating a potential upside of 39.13%. Given Genus' stronger consensus rating and higher probable upside, analysts clearly believe Genus is more favorable than City of London.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
City of London	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Genus	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

City of London has higher earnings, but lower revenue than Genus. City of London is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
City of London	£568.96M	4.91	£294.08M	£113.99	4.81
Genus	£672M	2.28	£7.87M	£71.00	32.56

In the previous week, Genus had 2 more articles in the media than City of London. MarketBeat recorded 6 mentions for Genus and 4 mentions for City of London. City of London's average media sentiment score of 1.21 beat Genus' score of 0.21 indicating that City of London is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
City of London	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genus	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

City of London and Genus tied by winning 9 of the 18 factors compared between the two stocks.

How does Genus compare to WH Smith?

Genus (LON:GNS) and WH Smith (LON:SMWH) are both small-cap personal services companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

Genus has a net margin of 7.07% compared to WH Smith's net margin of -9.48%. Genus' return on equity of 9.70% beat WH Smith's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genus	7.07%	9.70%	3.31%
WH Smith	-9.48%	-90.46%	6.62%

WH Smith has higher revenue and earnings than Genus. WH Smith is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genus	£672M	2.28	£7.87M	£71.00	32.56
WH Smith	£1.59B	0.36	£63.01M	-£96.70	N/A

53.1% of Genus shares are held by institutional investors. Comparatively, 71.9% of WH Smith shares are held by institutional investors. 0.7% of Genus shares are held by company insiders. Comparatively, 1.0% of WH Smith shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Genus currently has a consensus target price of GBX 3,216.67, indicating a potential upside of 39.13%. WH Smith has a consensus target price of GBX 720.50, indicating a potential upside of 58.14%. Given WH Smith's higher possible upside, analysts clearly believe WH Smith is more favorable than Genus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genus	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
WH Smith	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Genus had 6 more articles in the media than WH Smith. MarketBeat recorded 6 mentions for Genus and 0 mentions for WH Smith. Genus' average media sentiment score of 0.21 beat WH Smith's score of 0.00 indicating that Genus is being referred to more favorably in the media.

Company	Overall Sentiment
Genus	Neutral
WH Smith	Neutral

Genus has a beta of 0.895, indicating that its share price is 11% less volatile than the broader market. Comparatively, WH Smith has a beta of 0.915, indicating that its share price is 9% less volatile than the broader market.

Genus pays an annual dividend of GBX 32 per share and has a dividend yield of 1.4%. WH Smith pays an annual dividend of GBX 17.30 per share and has a dividend yield of 3.8%. Genus pays out 45.1% of its earnings in the form of a dividend. WH Smith pays out -17.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. WH Smith is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

WH Smith beats Genus on 9 of the 17 factors compared between the two stocks.

Get Genus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GNS vs. The Competition

Export

Metric	Genus	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£1.54B	£463.61M	£6.30B	£2.78B
Dividend Yield	1.45%	3.86%	2.79%	6.09%
P/E Ratio	32.56	3.80	21.00	365.88
Price / Sales	2.28	7,927.41	554.55	88,361.46
Price / Cash	50.56	13.13	42.94	27.89
Price / Book	2.79	81.62	9.75	7.64
Net Income	£7.87M	-£96.07M	£3.55B	£5.89B
7 Day Performance	-2.15%	1.09%	-0.53%	0.47%
1 Month Performance	-14.01%	1.05%	1.20%	2.49%
1 Year Performance	9.83%	71.17%	41.22%	87.07%

Genus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GNS Genus	3.5799 of 5 stars	GBX 2,312 +1.1%	GBX 3,216.67 +39.1%	+8.3%	£1.54B	£672M	32.56	480	News Coverage Positive News Analyst Forecast Insider Trade
IGG IG Group	N/A	GBX 1,530 -0.2%	GBX 1,302 -14.9%	+40.0%	£5.07B	£949.10M	14.56	2,754
DPH Dechra Pharmaceuticals	N/A	N/A	N/A	N/A	£4.40B	£761.50M	N/A	2,457
HWDN Howden Joinery Group	N/A	GBX 777.50 +1.6%	GBX 924 +18.8%	-12.4%	£4.19B	£2.42B	15.87	12,000	Gap Up
CTY City of London	N/A	GBX 551.70 +0.9%	N/A	+15.6%	£2.80B	£568.96M	4.84	N/A	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:GNS) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genus (GNS) Competitors

GNS vs. IGG, DPH, HWDN, CTY, and SMWH

How does Genus compare to IG Group?

Summary

How does Genus compare to Dechra Pharmaceuticals?

Summary

How does Genus compare to Howden Joinery Group?

Summary

How does Genus compare to City of London?

Summary

How does Genus compare to WH Smith?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNS vs. The Competition

Genus Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Genus (GNS) Competitors

GNS vs. IGG, DPH, HWDN, CTY, and SMWH

How does Genus compare to IG Group?

Do insiders and institutionals hold more shares of IGG or GNS?

Is IGG or GNS more profitable?

Which has more risk and volatility, IGG or GNS?

Do analysts recommend IGG or GNS?

Does the media prefer IGG or GNS?

Is IGG or GNS a better dividend stock?

Which has stronger earnings and valuation, IGG or GNS?

Summary

How does Genus compare to Dechra Pharmaceuticals?

Is GNS or DPH a better dividend stock?

Do institutionals & insiders have more ownership in GNS or DPH?

Which has preferable valuation and earnings, GNS or DPH?

Does the media refer more to GNS or DPH?

Which has more risk & volatility, GNS or DPH?

Do analysts rate GNS or DPH?

Is GNS or DPH more profitable?

Summary

How does Genus compare to Howden Joinery Group?

Is GNS or HWDN a better dividend stock?

Do insiders and institutionals hold more shares of GNS or HWDN?

Which has better valuation & earnings, GNS or HWDN?

Does the media prefer GNS or HWDN?

Which has more volatility & risk, GNS or HWDN?

Is GNS or HWDN more profitable?

Do analysts rate GNS or HWDN?

Summary

How does Genus compare to City of London?

Do insiders & institutionals believe in CTY or GNS?

Is CTY or GNS more profitable?

Which has more risk and volatility, CTY or GNS?

Is CTY or GNS a better dividend stock?

Do analysts rate CTY or GNS?

Which has better valuation & earnings, CTY or GNS?

Does the media refer more to CTY or GNS?

Summary

How does Genus compare to WH Smith?

Is GNS or SMWH more profitable?

Which has better valuation & earnings, GNS or SMWH?

Do institutionals and insiders hold more shares of GNS or SMWH?

Do analysts recommend GNS or SMWH?

Does the media refer more to GNS or SMWH?

Which has more risk & volatility, GNS or SMWH?

Is GNS or SMWH a better dividend stock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNS vs. The Competition

Genus Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools